PTC Therapeutics up as European regulator to reevaluate its opinion on muscle disorder drug

** Shares of drugmaker PTC Therapeutics PTCT rise 20.4% to $39.86

** Co says European Commission (EC) has decided not to adopt the European health regulator's advisory panel's negative opinion of co's muscle disorder drug called Translarna

** Says the EC has returned the opinion to the health regulator's advisory panel for re-evaluation

** As a result, Translarna remains available for patients in Europe - PTCT

** The EC has asked the panel to "further consider the totality of evidence, including data from patient registries and real-world evidence, in a revised opinion" co says

** "We believe the EC's decision is likely reflective of intense backlash from physicians and patient advocates who have no other therapeutic options and view Translarna as a safe and effective treatment..." William Blair analyst Sami Corwin says

** Including session moves, stock up 44.2% YTD